{
  "docId": "019de076-08a6-76d8-a7d9-b68643d71f6f",
  "docSlug": "3a0354fd1e64f16191ffa0e33db132fd",
  "documentTitle": "MaxCyte | Investor Presentation Deck | 19 slides",
  "authorId": "maxcyte",
  "authorName": "MaxCyte",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 15,
  "pageCount": 19,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "overcrowded",
  "nDataPoints": 5,
  "notes": "The slide uses a wave-based visual metaphor to represent sequential growth phases.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-08a6-76d8-a7d9-b68643d71f6f/15",
  "deckHref": "/decks/019de076-08a6-76d8-a7d9-b68643d71f6f",
  "deckJsonHref": "/decks/019de076-08a6-76d8-a7d9-b68643d71f6f.json",
  "deckAnchorHref": "/decks/019de076-08a6-76d8-a7d9-b68643d71f6f#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.7,
        "w": 0.19,
        "x": 0.4,
        "y": 0.18
      },
      "kind": "list",
      "text": "Third Wave: 8 Potential Approved Partner Programs, Launch Potential: 2028-2030, SPL Programs: Undisclosed, Example Indications: Solid Tumors, Lymphoma/Leukemia, Multiple Myeloma, Sickle Cell Disease, Beta-Thalassemia",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0f0b902d-189e-49a0-840e-1da2cd5d8523",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.19,
        "x": 0.21,
        "y": 0.18
      },
      "kind": "list",
      "text": "Second Wave: 7 Potential Approved Partner Programs, Launch Potential: 2025-2027, SPL Programs: SPL Partner A Program 1, SPL Partner A Program 2, Caribou's CB-010, Editas' EDIT-301, Precision Bio's Azer-cel, Vor's Trem-cel, Invios' APN401, Indications: Lymphoma/Leukemia, Solid Tumors, Sickle Cell Disease, Beta-Thalassemia",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "141ec9d2-a4f1-412c-a56d-78702495e6e3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.19,
        "x": 0.02,
        "y": 0.18
      },
      "kind": "list",
      "text": "First Wave: 1 Potential Approved Partner Program, Launch Potential: 2024, SPL Program: Vertex's Exa-Cel, Indications: Sickle Cell Disease, Beta-Thalassemia",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "178a1fc3-b1b0-4443-a76e-6fff2f1b9c2c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.19,
        "x": 0.59,
        "y": 0.18
      },
      "kind": "list",
      "text": "Fourth Wave: 20+ Additional Preclinical Partner Programs, Launch Potential: 2030+, Example Indications: Solid Tumors, Autoimmune Diseases, Neurodegenerative Diseases, Genetic Diseases, Lymphoma/Leukemia",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7c282ec0-b348-497a-be1d-0b9b8dbc2c65",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.19,
        "x": 0.78,
        "y": 0.18
      },
      "kind": "list",
      "text": "Fifth Wave: Additional Licensed Programs and New Partnerships Signed, Launch Potential: 2032+",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c62e7f83-0d35-459e-8146-46ab111e859c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.15,
        "x": 0.02,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "Source: Evaluate Pharma",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "783c6ee6-67e9-4d82-966b-9f68c62442ed",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.68,
        "x": 0.02,
        "y": 0.04
      },
      "kind": "title",
      "text": "MaxCyte Partnerships – Near and Long-Term Revenue Potential with Strong Upside in Commercial Opportunity",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "32fb70ea-10bd-4d87-850c-69f6f9860f88",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "timeline",
      "slug": null,
      "matchId": "29772201-3ded-4195-b4a3-a9c7d3c34661",
      "evidence": "Sequential waves representing future growth phases",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}